Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma.
- Author:
Yong-Lin CAI
1
;
Jun LI
;
Ai-Ying LU
;
Wei-Ming ZHONG
;
Yu-Ming ZHENG
;
Jian-Quan GAO
;
Hong ZENG
;
Wan-Sheng CHEN
;
Wei LIANG
;
Min-Zhong TANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antibodies, Viral; blood; Antigens, Viral; immunology; Capsid Proteins; immunology; Carcinoma; Child; Female; Herpesvirus 4, Human; immunology; Humans; Immunoglobulin A; blood; Male; Middle Aged; Nasopharyngeal Neoplasms; mortality; virology; Prognosis
- From: Chinese Journal of Experimental and Clinical Virology 2013;27(2):119-122
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThis study was aimed to investigate the association between serum against Epstein-Barr virus (EBV) antibodies levels and nasopharyngeal carcinoma (NPC) patients' prognosis.
METHODSBlood samples from 140 primary NPC patients without metastasis were collected before and after treatment. The titers of VCA/IgA and EA/IgA were detected by immunoenzyme assay, and the levels of NA1/IgA and Rta/IgG were detected by enzyme-linked immunosorbent assay (ELISA). All patients received consequent follow-up and long-term efficacy and survival assessment.
RESULTSPost-treatment serum levels of VCA/IgA, EA/IgA, NA1/IgA and Rta/IgG in NPC patients significantly decreased than those before treatment, while had significantly higher than those in control individuals (P < 0.05). Patients in remission had significantly lower pre-treatment serum levels of VCA/IgA and EA/IgA than patients with progression (P < 0.05). None of serum levels of VCA/IgA, EA/IgA, NA1/IgA and Rta/IgG was associated with the 3-year overall survival (P > 0.05). The progression-free survivals were significantly lower in patients with higher pre-treatment VCA/IgA (> or = 1 : 320) and EA/IgA (> or = 1:80) levels than in those with lower VCA/IgA ( < 1 : 320) and EA/IgA (< 1 : 80) levels, respectively (61.8% vs. 86.5% , 61.3% vs. 86.5%, P < 0.001). Cox regression model analysis demonstrated that pre-treatment serum VCA/IgA level was an independent risk factor for progression-free survival (HR = 3.80, P = 0.001).
CONCLUSIONAnti-EBV VCA/IgA and EA/IgA might provide information regarding the prognosis of NPC patients.